The GAUSS-@ ( Goal Achievement after Utilizing an Anti-PCSK@ Antibody in Statin Intolerant Subjects ) trial was a @-week , double-blind study of randomized patients ( @:@:@:@ ) to evolocumab @ mg every two weeks ( Q@W ) or evolocumab @ mg once monthly ( QM ) both with daily oral placebo or subcutaneous placebo Q@W or QM both with daily oral ezetimibe @ mg .